SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Rationale : Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-
like peptide-1 (GLP-1) receptor dual agonist. The efficacy and safety of once-weekly
tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are
unknown.

Abstract

Participants : Type 2 Diabetes with HbA1c between ≥7.0% and ≤10.5%
Metformin >1500 mg/day for at least 3 months prior to screening
Body Mass Index (BMI) ≥25 kg/m²

Intervention : Tirzepatide 5-15mg SQ q1w versus Semaglutide 1mg SQ q1w

Outcome : % Change in glycated hemoglobin level from baseline to 40 weeks. Estimated difference, – 0.45 ; 95% CI, – 0.57 to – 0.32; P value <0.001

Infographic

Reference

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515.

>